IN2014DN10088A - - Google Patents

Info

Publication number
IN2014DN10088A
IN2014DN10088A IN10088DEN2014A IN2014DN10088A IN 2014DN10088 A IN2014DN10088 A IN 2014DN10088A IN 10088DEN2014 A IN10088DEN2014 A IN 10088DEN2014A IN 2014DN10088 A IN2014DN10088 A IN 2014DN10088A
Authority
IN
India
Prior art keywords
dementia
salt
disease
senile dementia
senile
Prior art date
Application number
Other languages
English (en)
Inventor
Martin Hans Bohlin
Craig Robert Stewart
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IN2014DN10088A publication Critical patent/IN2014DN10088A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IN10088DEN2014 2012-06-21 2013-06-20 IN2014DN10088A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261662592P 2012-06-21 2012-06-21
PCT/GB2013/051606 WO2013190302A1 (en) 2012-06-21 2013-06-20 Camsylate salt

Publications (1)

Publication Number Publication Date
IN2014DN10088A true IN2014DN10088A (ja) 2015-08-21

Family

ID=48746084

Family Applications (1)

Application Number Title Priority Date Filing Date
IN10088DEN2014 IN2014DN10088A (ja) 2012-06-21 2013-06-20

Country Status (42)

Country Link
US (1) US10548882B2 (ja)
EP (2) EP3064494A1 (ja)
JP (2) JP2015520221A (ja)
KR (1) KR102123708B1 (ja)
CN (2) CN104411697B (ja)
AP (2) AP2014008137A0 (ja)
AR (2) AR091495A1 (ja)
AU (2) AU2013279109B2 (ja)
BR (2) BR112014031531B1 (ja)
CA (1) CA2875589C (ja)
CL (1) CL2014003374A1 (ja)
CO (1) CO7151486A2 (ja)
CR (2) CR20140571A (ja)
CY (1) CY1119505T1 (ja)
DK (1) DK2864316T3 (ja)
DO (1) DOP2014000268A (ja)
EC (1) ECSP14032215A (ja)
ES (1) ES2618939T3 (ja)
HK (1) HK1206349A1 (ja)
HR (1) HRP20170359T1 (ja)
HU (1) HUE033376T2 (ja)
IL (1) IL236131A0 (ja)
IN (1) IN2014DN10088A (ja)
LT (1) LT2864316T (ja)
MA (2) MA39259B1 (ja)
ME (1) ME02633B (ja)
MX (1) MX354214B (ja)
NI (1) NI201400146A (ja)
NZ (2) NZ702742A (ja)
PE (1) PE20150670A1 (ja)
PH (2) PH12014502803B1 (ja)
PL (1) PL2864316T3 (ja)
PT (1) PT2864316T (ja)
RS (1) RS55815B1 (ja)
RU (1) RU2638175C2 (ja)
SG (1) SG11201407934UA (ja)
SI (1) SI2864316T1 (ja)
TN (1) TN2014000491A1 (ja)
TW (2) TWI588140B (ja)
UA (1) UA114196C2 (ja)
WO (1) WO2013190302A1 (ja)
ZA (1) ZA201500408B (ja)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8415483B2 (en) 2010-12-22 2013-04-09 Astrazeneca Ab Compounds and their use as BACE inhibitors
WO2013054108A1 (en) 2011-10-10 2013-04-18 Astrazeneca Ab Mono-fluoro beta-secretase inhibitors
US9000182B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab 2H-imidazol-4-amine compounds and their use as BACE inhibitors
US9000183B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab Cyclohexane-1,2′-indene-1′,2″-imidazol compounds and their use as BACE inhibitors
US9000184B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab Cyclohexane-1,2′-naphthalene-1′,2″-imidazol compounds and their use as BACE inhibitors
US9000185B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab Cycloalkyl ether compounds and their use as BACE inhibitors
US10053453B2 (en) 2014-10-07 2018-08-21 Astrazeneca Ab Compounds and their use as BACE inhibitors
JP6546410B2 (ja) * 2015-02-23 2019-07-17 ローム株式会社 電力供給装置、acアダプタ、acチャージャ、電子機器および電力供給システム
CA3017418A1 (en) * 2016-03-15 2017-09-21 Astrazeneca Ab Combination of a bace inhibitor and an antibody or antigen-binding fragment for the treatment of a disorder associated with the accumulation of amyloid beta
TW201740944A (zh) 2016-03-15 2017-12-01 美國禮來大藥廠 組合療法
CN113573709A (zh) * 2019-03-14 2021-10-29 阿斯利康(瑞典)有限公司 用于体重减轻的兰比斯特

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100452491B1 (ko) * 2001-03-29 2004-10-12 한미약품 주식회사 신규한 결정형 암로디핀 캠실레이트 염 및 그의 제조방법
WO2002098462A1 (fr) 2001-06-01 2002-12-12 Ono Pharmaceutical Co., Ltd. Remedes contenant un inhibiteur d'aldose reductase en tant qu'agent actif destines a des troubles de demyelinisation ou des troubles associes a la demyelinisation
US7592348B2 (en) 2003-12-15 2009-09-22 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7915424B2 (en) 2004-03-22 2011-03-29 Eli Lilly And Company Pyridyl derivatives and their use as mGlu5 antagonists
TW201004961A (en) 2005-06-14 2010-02-01 Schering Corp Aspartyl protease inhibitors
CN101360716A (zh) 2005-11-21 2009-02-04 阿斯利康(瑞典)有限公司 新颖的2-氨基-咪唑-4-酮化合物及其在制备用于治疗认知缺损、阿尔茨海默病、神经变性和痴呆的药物中的用途
TW200734311A (en) 2005-11-21 2007-09-16 Astrazeneca Ab New compounds
EP1966163A1 (en) 2005-12-21 2008-09-10 Boehringer Ingelheim International GmbH Pyrimidine derivatives useful as inhibitors of pkc-theta
WO2007100536A1 (en) 2006-02-24 2007-09-07 Wyeth DIHYDROSPIRO[DIBENZO[A,D][7]ANNULENE-5,4'-IMIDAZOL] COMPOUNDS FOR THE INHIBITION OF β-SECRETASE
US8168641B2 (en) 2006-06-12 2012-05-01 Schering Corporation Aspartyl protease inhibitors
WO2008076044A1 (en) 2006-12-20 2008-06-26 Astrazeneca Ab Novel 2-amino-5, 5-diaryl-imidazol-4-ones
EP2108018A2 (en) 2007-02-01 2009-10-14 Glaxo Group Limited 8-oxa-1,4-diazaspiro [4,5] dec-3-en-1-yl and 1,4,8-triazaspiro [4,5] dec-3-en-1-yl acetamides as glyti transporter inhibitors in treatment of neurological and neuropsychiatric disorders
CN101809019A (zh) 2007-05-07 2010-08-18 先灵公司 γ分泌酶调节剂
EP2249646A4 (en) 2008-02-06 2013-09-25 Glaxo Group Ltd PDE4 muscarinic Antagonist-DOPPELPHARMACOPHOREN
FR2929943B1 (fr) * 2008-04-15 2010-09-24 Inst Rech Developpement Ird Sels de quinoleines 2-substituees
CA2731209A1 (en) 2008-07-28 2010-02-04 Eisai R&D Management Co., Ltd. Spiroaminodihydrothiazine derivatives
WO2010021680A2 (en) 2008-08-19 2010-02-25 Vitae Pharmaceuticals, Inc. Inhibitors of beta-secretase
AU2009291602B2 (en) 2008-09-11 2013-02-14 Amgen Inc. Spiro-tetracyclic ring compounds as betasecretase modulators and methods of use
NZ594230A (en) 2009-03-13 2013-11-29 Vitae Pharmaceuticals Inc Inhibitors of beta-secretase
UY32751A (es) 2009-07-02 2011-01-31 Astrazeneca Ab Imidazoles sustituidos y uso de los mismos
AR077365A1 (es) 2009-07-02 2011-08-24 Astrazeneca Ab Derivados de imidazol para el tratamiento de enfermedades mediadas por la inhibicion de la formacion de abeta
EP2539322B1 (en) 2010-02-24 2014-01-01 Vitae Pharmaceuticals, Inc. Inhibitors of beta-secretase
AR080865A1 (es) 2010-03-31 2012-05-16 Array Biopharma Inc Derivados de espirotetrahidronaftaleno, composiciones farmaceuticas que los contienen, proceso de preparacion y uso de los mismos para tratar enfermedades neurodegenerativas,tal como alzheimer.
WO2011130741A1 (en) 2010-04-16 2011-10-20 Array Biopharma Inc. Compounds for treating neurodegenerative diseases
US8921363B2 (en) 2010-08-05 2014-12-30 Amgen Inc. Derivatives of 1 H-isoindol-3-amine, 1 H-iso-aza-indol-3amine, 3,4-dihydroisoquinolin-1-amine, and 1,4-dihydroisoquinolin-3-amine as beta-secretase inhibitors
WO2012040641A2 (en) 2010-09-24 2012-03-29 Array Biopharma Inc. Compounds for treating neurodegenerative diseases
WO2012071458A1 (en) 2010-11-22 2012-05-31 Array Biopharma Inc. Heterocyclic inhibitors of beta - secretase for the treatment of neurodegenerative diseases
US8415483B2 (en) 2010-12-22 2013-04-09 Astrazeneca Ab Compounds and their use as BACE inhibitors
WO2013054108A1 (en) 2011-10-10 2013-04-18 Astrazeneca Ab Mono-fluoro beta-secretase inhibitors
US9000185B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab Cycloalkyl ether compounds and their use as BACE inhibitors
US9000184B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab Cyclohexane-1,2′-naphthalene-1′,2″-imidazol compounds and their use as BACE inhibitors
US9000182B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab 2H-imidazol-4-amine compounds and their use as BACE inhibitors
US9000183B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab Cyclohexane-1,2′-indene-1′,2″-imidazol compounds and their use as BACE inhibitors

Also Published As

Publication number Publication date
HK1206349A1 (zh) 2016-01-08
ECSP14032215A (es) 2015-12-31
MX354214B (es) 2018-02-19
AU2017254965B2 (en) 2019-05-09
RU2014148305A (ru) 2016-08-10
HRP20170359T1 (hr) 2017-05-05
EP2864316A1 (en) 2015-04-29
US10548882B2 (en) 2020-02-04
TWI639591B (zh) 2018-11-01
JP2018104448A (ja) 2018-07-05
HUE033376T2 (en) 2017-11-28
AU2013279109A1 (en) 2015-01-15
CA2875589A1 (en) 2013-12-27
CR20160202A (es) 2016-07-26
TN2014000491A1 (en) 2016-03-30
TW201406745A (zh) 2014-02-16
CN104411697B (zh) 2016-08-10
PT2864316T (pt) 2017-02-24
CO7151486A2 (es) 2014-12-29
TWI588140B (zh) 2017-06-21
ES2618939T3 (es) 2017-06-22
BR112014031531B1 (pt) 2022-08-02
CY1119505T1 (el) 2018-03-07
MA39259A1 (fr) 2017-12-29
ME02633B (me) 2017-06-20
BR122016014302A2 (pt) 2019-08-27
ZA201500408B (en) 2016-10-26
BR112014031531A2 (pt) 2017-06-27
NZ702742A (en) 2016-12-23
PH12016500498A1 (en) 2017-04-10
MA39259B1 (fr) 2018-09-28
BR122016014302B1 (pt) 2022-08-23
NZ727045A (en) 2018-06-29
AU2017254965A1 (en) 2017-11-23
JP2015520221A (ja) 2015-07-16
NI201400146A (es) 2016-09-21
MA37666A1 (fr) 2016-04-29
AR105176A2 (es) 2017-09-13
CL2014003374A1 (es) 2015-02-27
DOP2014000268A (es) 2015-04-15
UA114196C2 (uk) 2017-05-10
MX2014014709A (es) 2015-03-04
PH12014502803A1 (en) 2015-02-23
AU2013279109B2 (en) 2017-08-31
JP6509393B2 (ja) 2019-05-08
SG11201407934UA (en) 2015-01-29
EP2864316B1 (en) 2016-12-14
KR102123708B1 (ko) 2020-06-16
TW201730177A (zh) 2017-09-01
AP2017009693A0 (en) 2017-01-31
MA37666B1 (fr) 2016-12-30
CN106279102A (zh) 2017-01-04
EP3064494A1 (en) 2016-09-07
DK2864316T3 (en) 2017-03-20
AR091495A1 (es) 2015-02-11
IL236131A0 (en) 2015-02-01
PH12014502803B1 (en) 2015-02-23
CA2875589C (en) 2020-08-25
PE20150670A1 (es) 2015-06-03
CN104411697A (zh) 2015-03-11
KR20150023388A (ko) 2015-03-05
WO2013190302A1 (en) 2013-12-27
CR20140571A (es) 2015-02-04
SI2864316T1 (sl) 2017-04-26
US20140031379A1 (en) 2014-01-30
AP2014008137A0 (en) 2014-12-31
RS55815B1 (sr) 2017-08-31
LT2864316T (lt) 2017-03-27
RU2638175C2 (ru) 2017-12-12
PL2864316T3 (pl) 2017-09-29

Similar Documents

Publication Publication Date Title
IN2014DN10088A (ja)
PH12016501192A1 (en) Tetrahydropyridopyrazines modulators of gpr6
MD20140109A2 (ro) Compuşi ai indolului şi indazolului care activează AMPK
WO2012096929A3 (en) Heteroaryl compounds and methods of use thereof
MX351368B (es) Compuestos heteroarilo y metodos para utilizarlos.
MD20150091A2 (ro) Compuşi antivirali
CL2012002487A1 (es) Compuestos derivados de imidazo[1,2-a]pirazina, inhibidores de pde10; composicion farmacéutica que los comprende; proceso para preparar la composicion farmaceutica; utiles para el tratamiento de enfermedades neurológicas, psiquiátricas o metabólicas tales como esquizofrenia, parkinson y diabetes, entre otras.
PH12015500860A1 (en) 2-phenyl -5- heterocyclyl -tetrahydro-2h- pyran-3-amine compounds for use in the treatment of diabetes and its associated disorders
MX2011008825A (es) 3-aminoisoxazolopiridinas sustituidas como moduladores de kcnq2/3.
MX2011008662A (es) 2-mercapto-3-aminopiridinas sustituidas como moduladores de kcnq2/3.
MX2011009338A (es) 3-amino-2-mercaptoquinolinas sustituidas como moduladores de kcnq2/3.
ZA201407010B (en) Process for the preparation of branched polybutadiene having high content of 1,4-cis units
WO2016005962A3 (en) Stable liquid formulations of cyclophosphamide and processes
IN2014DN09584A (ja)
MY192609A (en) Substituted bicyclic heteroaryl compounds as rxr agonists
NZ702239A (en) Heteroaryl compounds and methods of use thereof
NZ707946A (en) Hydantoin derivative
CO7160082A2 (es) Un método para mejorar la función hepática
MX2013011732A (es) Derivados de isoindolinona.
WO2013114403A8 (en) Substituted 4,5-dihydro-2h-benzo[e]indazole-9-carboxylates for the treatment of diabetes and related disorders